Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Job Trends

Bioinformatics Roles in Increasing Demand, Critical to Industry, Personalized Medicine

Bioinformatics is on the rise, forecasted to grow by about $16 billion from 2024 to 2029 given its value to managing mass datasets critical to modern drug discovery and development. Two talent acquisition experts share how the field has evolved in the past few years and which skills are most in demand.

July 3, 2025

5 min read

Angela Gabriel

vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake

Immunology and inflammation

Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition

Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

July 3, 2025

2 min read

Tristan Manalac

Close-Up Of Syringe With Bottles Against Blue Background

RSV

Kennedy Follows RSV Recommendations of ACIP Members He Fired

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are at risk of severe disease.

July 3, 2025

3 min read

Tristan Manalac

Minimal icon featuring open blue padlock with white upward arrow passing through it, symbolizing security, access, or unlocking new opportunities, digital access, data protection, 3d rendering

Accelerated approval

Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing convenience and efficacy.

July 3, 2025

2 min read

Tristan Manalac

Megaphone with stethoscope isolated on orange background. 3d illustration

Women’s health

Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone

An open letter signed by more than 50 industry executives blasts a “fundamentally, fatally flawed” report that urges greater restrictions on the abortion pill.

July 3, 2025

2 min read

Tristan Manalac

Painful female periods concept. Vector flat character illustration. Woman standing and suffering menstrual abdominal pain isolated on pink background. Design for health care.

Women’s Health

Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

July 2, 2025

1 min read

Annalee Armstrong

Collage of gavel, safety cones and roadblock

Legal

Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful

As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement sweeping changes to the structure of the agency as created by Congress, a judge wrote.

July 2, 2025

2 min read

Tristan Manalac

Government

RFK Jr. Eyes Changes to Vaccine Injury Compensation Program

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of limitations” to more than three years.

July 2, 2025

2 min read

Tristan Manalac